CRISPR Therapeutics director proposes $720K sale
The notice lists an aggregate market value of $720,373.36 and names Morgan Stanley Smith Barney LLC as broker.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CRISPR Therapeutics AG director Simeon George reported a proposed sale of 14,514 common shares, with October 14, 2026, listed as the approximate sale date. The listed aggregate market value is $720,373.36; Morgan Stanley Smith Barney LLC is named as broker and NASDAQ as the exchange. The shares are listed as acquired from the issuer through a stock option exercise for cash on October 14, 2026.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.